Structured Review

Gen-Probe hcv rna
Experimental design and sequence of plasma infusions and follow-up of chimpanzees. Experiment I assessed the infectivity of plasma that tested <t>HCV</t> <t>RNA</t> negative by licensed diagnostic assays and was obtained in the days just before ramp-up viremia. (A)
Hcv Rna, supplied by Gen-Probe, used in various techniques. Bioz Stars score: 92/100, based on 14 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/hcv rna/product/Gen-Probe
Average 92 stars, based on 14 article reviews
Price from $9.99 to $1999.99
hcv rna - by Bioz Stars, 2020-05
92/100 stars

Images

1) Product Images from "Infectivity in chimpanzees (Pan troglodytes) of plasma collected before HCV RNA detectability by FDA-licensed assays: implications for transfusion safety and HCV infection outcomes"

Article Title: Infectivity in chimpanzees (Pan troglodytes) of plasma collected before HCV RNA detectability by FDA-licensed assays: implications for transfusion safety and HCV infection outcomes

Journal: Blood

doi: 10.1182/blood-2011-12-393637

Experimental design and sequence of plasma infusions and follow-up of chimpanzees. Experiment I assessed the infectivity of plasma that tested HCV RNA negative by licensed diagnostic assays and was obtained in the days just before ramp-up viremia. (A)
Figure Legend Snippet: Experimental design and sequence of plasma infusions and follow-up of chimpanzees. Experiment I assessed the infectivity of plasma that tested HCV RNA negative by licensed diagnostic assays and was obtained in the days just before ramp-up viremia. (A)

Techniques Used: Sequencing, Infection, Diagnostic Assay

2) Product Images from "Induction of CXCR3- and CCR5-associated Chemokines during Acute Hepatitis C Virus Infection"

Article Title: Induction of CXCR3- and CCR5-associated Chemokines during Acute Hepatitis C Virus Infection

Journal: Journal of hepatology

doi: 10.1016/j.jhep.2010.12.033

Individual plots illustrating HCV RNA, chemokine, and ALT values for the nine subjects included in the study Left Y-axis indicates ALT and chemokine levels and right Y-axis indicates HCV RNA levels. Days before and after viral acquisition are indicated along the X-axis. Individual parameters are indicated in the figure legend shown in the upper left panel. Dots along the X-axis represent qualitative HCV RNA results with blue indicating a negative result and red indicating a positive result. Infection outcome is noted in the upper left hand corner above each illustration.
Figure Legend Snippet: Individual plots illustrating HCV RNA, chemokine, and ALT values for the nine subjects included in the study Left Y-axis indicates ALT and chemokine levels and right Y-axis indicates HCV RNA levels. Days before and after viral acquisition are indicated along the X-axis. Individual parameters are indicated in the figure legend shown in the upper left panel. Dots along the X-axis represent qualitative HCV RNA results with blue indicating a negative result and red indicating a positive result. Infection outcome is noted in the upper left hand corner above each illustration.

Techniques Used: Infection

Detailed evaluation of subject 00105 Between days 0 and 540 after viral acquisition, subject 00105 had approximately weekly sampling that enabled us to identify A) Change-point, a qualitative change in HCV dynamics at approximately 210 days post infection. Log transformed HCV RNA, chemokines, and ALT levels are plotted and the smoothed trajectories for each parameter are computed as described in Methods. After the change-point, HCV RNA increases substantially with significantly smaller variance of CXCR3-associated chemokines and ALT. B) Spearman’s rank correlations at 0, 1 and 2 week lags. For 0-week correlations, quantities along the diagonal, from upper left to lower right, both before and after the change-point, are, by definition, 1.0. Correlations lagged by 0, 1, and 2 weeks in data obtained before (red) or after (blue) the change-point. The columns represent quantities lagged behind the rows.
Figure Legend Snippet: Detailed evaluation of subject 00105 Between days 0 and 540 after viral acquisition, subject 00105 had approximately weekly sampling that enabled us to identify A) Change-point, a qualitative change in HCV dynamics at approximately 210 days post infection. Log transformed HCV RNA, chemokines, and ALT levels are plotted and the smoothed trajectories for each parameter are computed as described in Methods. After the change-point, HCV RNA increases substantially with significantly smaller variance of CXCR3-associated chemokines and ALT. B) Spearman’s rank correlations at 0, 1 and 2 week lags. For 0-week correlations, quantities along the diagonal, from upper left to lower right, both before and after the change-point, are, by definition, 1.0. Correlations lagged by 0, 1, and 2 weeks in data obtained before (red) or after (blue) the change-point. The columns represent quantities lagged behind the rows.

Techniques Used: Sampling, Infection, Transformation Assay

Mean HCV RNA, chemokine, and ALT smoothed trajectories before and after HCV acquisition
Figure Legend Snippet: Mean HCV RNA, chemokine, and ALT smoothed trajectories before and after HCV acquisition

Techniques Used:

3) Product Images from "Frequent Longitudinal Sampling of Hepatitis C Virus Infection in Injection Drug Users Reveals Intermittently Detectable Viremia and Reinfection"

Article Title: Frequent Longitudinal Sampling of Hepatitis C Virus Infection in Injection Drug Users Reveals Intermittently Detectable Viremia and Reinfection

Journal: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America

doi: 10.1093/cid/cis921

Event timelines for reinfection cases ( A ), intercalation cases ( B ), and an unclassified case ( C ) with multiple genotypes. A , Hepatitis C virus (HCV) viremia (IU/mL), alanine aminotransferase (ALT), genotype (GT), HCV RNA, and anti-HCV results showing acute HCV infection, reinfection, and reclearance among young injection drug users (IDUs) who have previously cleared HCV infection. Visit dates are shown in the lower boxes. Gray boxes show new acute HCV infections and black boxes show reinfections. Participants whose first infection serology was consistent with that of previously resolved infection (anti-HCV positive and HCV RNA negative) are shown in scored boxes. ^ in the GT box indicates that GT was determined by serotyping. B , HCV viremia (IU/mL), ALT, GT, HCV RNA, and anti-HCV results showing acute HCV infection and intercalation among young IDUs. Visit dates are shown in the lower boxes. Light gray boxes show new acute HCV infections and intercalations. Participants whose first infection serology was consistent with that of previously resolved infection (anti-HCV positive and HCV RNA. negative) are shown with scored boxes. ^ in the GT box indicates that GT was determined by serotyping. C , HCV viremia (IU/mL), ALT, GT, HCV RNA, and anti-HCV results in a young IDU whose infection could not be classified as either reinfection or intercalation. Results show acute HCV infection and either coinfection or superinfection. Visit dates are shown in the lower boxes. Lighter gray boxes show new acute HCV infection and darker gray box shows infection with a different genotype. Abbreviations: ALT, alanine aminotransferase; GT, genotype; HCV, hepatitis C virus; IL28B, interleukin 28B.
Figure Legend Snippet: Event timelines for reinfection cases ( A ), intercalation cases ( B ), and an unclassified case ( C ) with multiple genotypes. A , Hepatitis C virus (HCV) viremia (IU/mL), alanine aminotransferase (ALT), genotype (GT), HCV RNA, and anti-HCV results showing acute HCV infection, reinfection, and reclearance among young injection drug users (IDUs) who have previously cleared HCV infection. Visit dates are shown in the lower boxes. Gray boxes show new acute HCV infections and black boxes show reinfections. Participants whose first infection serology was consistent with that of previously resolved infection (anti-HCV positive and HCV RNA negative) are shown in scored boxes. ^ in the GT box indicates that GT was determined by serotyping. B , HCV viremia (IU/mL), ALT, GT, HCV RNA, and anti-HCV results showing acute HCV infection and intercalation among young IDUs. Visit dates are shown in the lower boxes. Light gray boxes show new acute HCV infections and intercalations. Participants whose first infection serology was consistent with that of previously resolved infection (anti-HCV positive and HCV RNA. negative) are shown with scored boxes. ^ in the GT box indicates that GT was determined by serotyping. C , HCV viremia (IU/mL), ALT, GT, HCV RNA, and anti-HCV results in a young IDU whose infection could not be classified as either reinfection or intercalation. Results show acute HCV infection and either coinfection or superinfection. Visit dates are shown in the lower boxes. Lighter gray boxes show new acute HCV infection and darker gray box shows infection with a different genotype. Abbreviations: ALT, alanine aminotransferase; GT, genotype; HCV, hepatitis C virus; IL28B, interleukin 28B.

Techniques Used: Infection, Injection

4) Product Images from "Infectivity in chimpanzees (Pan troglodytes) of plasma collected before HCV RNA detectability by FDA-licensed assays: implications for transfusion safety and HCV infection outcomes"

Article Title: Infectivity in chimpanzees (Pan troglodytes) of plasma collected before HCV RNA detectability by FDA-licensed assays: implications for transfusion safety and HCV infection outcomes

Journal: Blood

doi: 10.1182/blood-2011-12-393637

Experimental design and sequence of plasma infusions and follow-up of chimpanzees. Experiment I assessed the infectivity of plasma that tested HCV RNA negative by licensed diagnostic assays and was obtained in the days just before ramp-up viremia. (A)
Figure Legend Snippet: Experimental design and sequence of plasma infusions and follow-up of chimpanzees. Experiment I assessed the infectivity of plasma that tested HCV RNA negative by licensed diagnostic assays and was obtained in the days just before ramp-up viremia. (A)

Techniques Used: Sequencing, Infection, Diagnostic Assay

5) Product Images from "Frequent Recovery and Broad Genotype 2 Diversity Characterize Hepatitis C Virus Infection in Ghana, West Africa"

Article Title: Frequent Recovery and Broad Genotype 2 Diversity Characterize Hepatitis C Virus Infection in Ghana, West Africa

Journal: Journal of Virology

doi: 10.1128/JVI.77.14.7914-7923.2003

RNA viral load in HCV-infected blood donors from Ghana and the United Kingdom. The horizontal bars denote median values.
Figure Legend Snippet: RNA viral load in HCV-infected blood donors from Ghana and the United Kingdom. The horizontal bars denote median values.

Techniques Used: Infection

Antigen reactivity of 43 HCV RNA-negative Ghanaian blood donations in two anti-HCV confirmatory assays.
Figure Legend Snippet: Antigen reactivity of 43 HCV RNA-negative Ghanaian blood donations in two anti-HCV confirmatory assays.

Techniques Used:

Related Articles

Multiplex Assay:

Article Title: Frequent Recovery and Broad Genotype 2 Diversity Characterize Hepatitis C Virus Infection in Ghana, West Africa
Article Snippet: .. HCV RNA was screened using the transcription-mediated amplification (TMA)-based HIV/HCV RNA multiplex assay (Procleix HIV-1/HCV assay, Gen-Probe Inc., San Diego, Calif., and Chiron Blood Testing, Emeryville, Calif.) according to the manufacturer's instructions, as previously described ( ). .. Viral RNA was extracted from 140 μl of plasma with a QIAamp Viral RNA Mini Kit (Qiagen Ltd, Crawley, United Kingdom) according to the manufacturer's instructions.

Amplification:

Article Title: Frequent Longitudinal Sampling of Hepatitis C Virus Infection in Injection Drug Users Reveals Intermittently Detectable Viremia and Reinfection
Article Snippet: .. Plasma samples were tested for HCV RNA using a nucleic acid amplification test, the discriminatory HCV transcription-mediated amplification (dHCV TMA) assay component of the Procleix human immunodeficiency virus type 1 (HIV-1)/HCV assay (Gen-Probe Inc, San Diego, CA; Novartis Vaccines and Diagnostics, Emeryville, CA). .. Repeatedly reactive samples were considered confirmed positive, and further tested to determine quantitative HCV RNA levels using either the HCV Monitor assay (Roche Amplicor Monitor HCV 2.0, Roche Molecular Systems) performed on the Cobas Amplicor semiautomatic instrument, or the Bayer HCV RNA branched DNA assay (Versant HCV 3.0; Bayer Diagnostics, Tarrytown, NY).

Article Title: HLA B*57 Does Not Fully Explain Hepatitis C Clearance in HIV Controllers
Article Snippet: .. HCV RNA was measured using discriminatory HCV transcription-mediated amplification (dTMA) assay component of the Procleix HIV-1/HCV assay, developed and manufactured by Gen-Probe (San Diego, CA) and marketed by Novartis Vaccines and Diagnostics. ..

Article Title: A Case-Control Study of Factors associated with Resolution of Hepatitis C viremia in Former Blood Donors
Article Snippet: .. Residual volume after NAT screening from all cases was retested by duplicate undiluted HCV RNA testing using dHCV Transcription-Mediated Amplification (TMA) (Gen-Probe Incorporated, San Diego, California). ..

Article Title: Frequent Recovery and Broad Genotype 2 Diversity Characterize Hepatitis C Virus Infection in Ghana, West Africa
Article Snippet: .. HCV RNA was screened using the transcription-mediated amplification (TMA)-based HIV/HCV RNA multiplex assay (Procleix HIV-1/HCV assay, Gen-Probe Inc., San Diego, Calif., and Chiron Blood Testing, Emeryville, Calif.) according to the manufacturer's instructions, as previously described ( ). .. Viral RNA was extracted from 140 μl of plasma with a QIAamp Viral RNA Mini Kit (Qiagen Ltd, Crawley, United Kingdom) according to the manufacturer's instructions.

Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 92
    Gen-Probe hcv rna
    Experimental design and sequence of plasma infusions and follow-up of chimpanzees. Experiment I assessed the infectivity of plasma that tested <t>HCV</t> <t>RNA</t> negative by licensed diagnostic assays and was obtained in the days just before ramp-up viremia. (A)
    Hcv Rna, supplied by Gen-Probe, used in various techniques. Bioz Stars score: 92/100, based on 14 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/hcv rna/product/Gen-Probe
    Average 92 stars, based on 14 article reviews
    Price from $9.99 to $1999.99
    hcv rna - by Bioz Stars, 2020-05
    92/100 stars
      Buy from Supplier

    Image Search Results


    Experimental design and sequence of plasma infusions and follow-up of chimpanzees. Experiment I assessed the infectivity of plasma that tested HCV RNA negative by licensed diagnostic assays and was obtained in the days just before ramp-up viremia. (A)

    Journal: Blood

    Article Title: Infectivity in chimpanzees (Pan troglodytes) of plasma collected before HCV RNA detectability by FDA-licensed assays: implications for transfusion safety and HCV infection outcomes

    doi: 10.1182/blood-2011-12-393637

    Figure Lengend Snippet: Experimental design and sequence of plasma infusions and follow-up of chimpanzees. Experiment I assessed the infectivity of plasma that tested HCV RNA negative by licensed diagnostic assays and was obtained in the days just before ramp-up viremia. (A)

    Article Snippet: Multiple additional replicates (n = 20 or 23) of selected eclipse-phase samples were also further tested for HCV RNA either by the dHCV assay or by the Procleix duplex (HIV-HCV) assay (Gen-Probe) as part of a previously published study.

    Techniques: Sequencing, Infection, Diagnostic Assay

    Individual plots illustrating HCV RNA, chemokine, and ALT values for the nine subjects included in the study Left Y-axis indicates ALT and chemokine levels and right Y-axis indicates HCV RNA levels. Days before and after viral acquisition are indicated along the X-axis. Individual parameters are indicated in the figure legend shown in the upper left panel. Dots along the X-axis represent qualitative HCV RNA results with blue indicating a negative result and red indicating a positive result. Infection outcome is noted in the upper left hand corner above each illustration.

    Journal: Journal of hepatology

    Article Title: Induction of CXCR3- and CCR5-associated Chemokines during Acute Hepatitis C Virus Infection

    doi: 10.1016/j.jhep.2010.12.033

    Figure Lengend Snippet: Individual plots illustrating HCV RNA, chemokine, and ALT values for the nine subjects included in the study Left Y-axis indicates ALT and chemokine levels and right Y-axis indicates HCV RNA levels. Days before and after viral acquisition are indicated along the X-axis. Individual parameters are indicated in the figure legend shown in the upper left panel. Dots along the X-axis represent qualitative HCV RNA results with blue indicating a negative result and red indicating a positive result. Infection outcome is noted in the upper left hand corner above each illustration.

    Article Snippet: The presence of HCV RNA was determined with the discriminatory HCV Aptima TMA assay (developed and marketed by Gen-Probe, San Diego, CA) [ ], with the lower limit of detection of 12.1 (95% confidence interval [CI] 11.1–13.2) copies of HCV RNA/mL.

    Techniques: Infection

    Detailed evaluation of subject 00105 Between days 0 and 540 after viral acquisition, subject 00105 had approximately weekly sampling that enabled us to identify A) Change-point, a qualitative change in HCV dynamics at approximately 210 days post infection. Log transformed HCV RNA, chemokines, and ALT levels are plotted and the smoothed trajectories for each parameter are computed as described in Methods. After the change-point, HCV RNA increases substantially with significantly smaller variance of CXCR3-associated chemokines and ALT. B) Spearman’s rank correlations at 0, 1 and 2 week lags. For 0-week correlations, quantities along the diagonal, from upper left to lower right, both before and after the change-point, are, by definition, 1.0. Correlations lagged by 0, 1, and 2 weeks in data obtained before (red) or after (blue) the change-point. The columns represent quantities lagged behind the rows.

    Journal: Journal of hepatology

    Article Title: Induction of CXCR3- and CCR5-associated Chemokines during Acute Hepatitis C Virus Infection

    doi: 10.1016/j.jhep.2010.12.033

    Figure Lengend Snippet: Detailed evaluation of subject 00105 Between days 0 and 540 after viral acquisition, subject 00105 had approximately weekly sampling that enabled us to identify A) Change-point, a qualitative change in HCV dynamics at approximately 210 days post infection. Log transformed HCV RNA, chemokines, and ALT levels are plotted and the smoothed trajectories for each parameter are computed as described in Methods. After the change-point, HCV RNA increases substantially with significantly smaller variance of CXCR3-associated chemokines and ALT. B) Spearman’s rank correlations at 0, 1 and 2 week lags. For 0-week correlations, quantities along the diagonal, from upper left to lower right, both before and after the change-point, are, by definition, 1.0. Correlations lagged by 0, 1, and 2 weeks in data obtained before (red) or after (blue) the change-point. The columns represent quantities lagged behind the rows.

    Article Snippet: The presence of HCV RNA was determined with the discriminatory HCV Aptima TMA assay (developed and marketed by Gen-Probe, San Diego, CA) [ ], with the lower limit of detection of 12.1 (95% confidence interval [CI] 11.1–13.2) copies of HCV RNA/mL.

    Techniques: Sampling, Infection, Transformation Assay

    Mean HCV RNA, chemokine, and ALT smoothed trajectories before and after HCV acquisition

    Journal: Journal of hepatology

    Article Title: Induction of CXCR3- and CCR5-associated Chemokines during Acute Hepatitis C Virus Infection

    doi: 10.1016/j.jhep.2010.12.033

    Figure Lengend Snippet: Mean HCV RNA, chemokine, and ALT smoothed trajectories before and after HCV acquisition

    Article Snippet: The presence of HCV RNA was determined with the discriminatory HCV Aptima TMA assay (developed and marketed by Gen-Probe, San Diego, CA) [ ], with the lower limit of detection of 12.1 (95% confidence interval [CI] 11.1–13.2) copies of HCV RNA/mL.

    Techniques:

    Event timelines for reinfection cases ( A ), intercalation cases ( B ), and an unclassified case ( C ) with multiple genotypes. A , Hepatitis C virus (HCV) viremia (IU/mL), alanine aminotransferase (ALT), genotype (GT), HCV RNA, and anti-HCV results showing acute HCV infection, reinfection, and reclearance among young injection drug users (IDUs) who have previously cleared HCV infection. Visit dates are shown in the lower boxes. Gray boxes show new acute HCV infections and black boxes show reinfections. Participants whose first infection serology was consistent with that of previously resolved infection (anti-HCV positive and HCV RNA negative) are shown in scored boxes. ^ in the GT box indicates that GT was determined by serotyping. B , HCV viremia (IU/mL), ALT, GT, HCV RNA, and anti-HCV results showing acute HCV infection and intercalation among young IDUs. Visit dates are shown in the lower boxes. Light gray boxes show new acute HCV infections and intercalations. Participants whose first infection serology was consistent with that of previously resolved infection (anti-HCV positive and HCV RNA. negative) are shown with scored boxes. ^ in the GT box indicates that GT was determined by serotyping. C , HCV viremia (IU/mL), ALT, GT, HCV RNA, and anti-HCV results in a young IDU whose infection could not be classified as either reinfection or intercalation. Results show acute HCV infection and either coinfection or superinfection. Visit dates are shown in the lower boxes. Lighter gray boxes show new acute HCV infection and darker gray box shows infection with a different genotype. Abbreviations: ALT, alanine aminotransferase; GT, genotype; HCV, hepatitis C virus; IL28B, interleukin 28B.

    Journal: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America

    Article Title: Frequent Longitudinal Sampling of Hepatitis C Virus Infection in Injection Drug Users Reveals Intermittently Detectable Viremia and Reinfection

    doi: 10.1093/cid/cis921

    Figure Lengend Snippet: Event timelines for reinfection cases ( A ), intercalation cases ( B ), and an unclassified case ( C ) with multiple genotypes. A , Hepatitis C virus (HCV) viremia (IU/mL), alanine aminotransferase (ALT), genotype (GT), HCV RNA, and anti-HCV results showing acute HCV infection, reinfection, and reclearance among young injection drug users (IDUs) who have previously cleared HCV infection. Visit dates are shown in the lower boxes. Gray boxes show new acute HCV infections and black boxes show reinfections. Participants whose first infection serology was consistent with that of previously resolved infection (anti-HCV positive and HCV RNA negative) are shown in scored boxes. ^ in the GT box indicates that GT was determined by serotyping. B , HCV viremia (IU/mL), ALT, GT, HCV RNA, and anti-HCV results showing acute HCV infection and intercalation among young IDUs. Visit dates are shown in the lower boxes. Light gray boxes show new acute HCV infections and intercalations. Participants whose first infection serology was consistent with that of previously resolved infection (anti-HCV positive and HCV RNA. negative) are shown with scored boxes. ^ in the GT box indicates that GT was determined by serotyping. C , HCV viremia (IU/mL), ALT, GT, HCV RNA, and anti-HCV results in a young IDU whose infection could not be classified as either reinfection or intercalation. Results show acute HCV infection and either coinfection or superinfection. Visit dates are shown in the lower boxes. Lighter gray boxes show new acute HCV infection and darker gray box shows infection with a different genotype. Abbreviations: ALT, alanine aminotransferase; GT, genotype; HCV, hepatitis C virus; IL28B, interleukin 28B.

    Article Snippet: Plasma samples were tested for HCV RNA using a nucleic acid amplification test, the discriminatory HCV transcription-mediated amplification (dHCV TMA) assay component of the Procleix human immunodeficiency virus type 1 (HIV-1)/HCV assay (Gen-Probe Inc, San Diego, CA; Novartis Vaccines and Diagnostics, Emeryville, CA).

    Techniques: Infection, Injection